表紙
市場調查報告書

非酒精性脂肪性肝炎 (NASH) 治療藥的開發平台、市場概要

NASH Drug Pipeline and Market Overview

出版商 Kalorama Information 商品編碼 924756
出版日期 內容資訊 英文 18 Pages
商品交期: 最快1-2個工作天內
價格
非酒精性脂肪性肝炎 (NASH) 治療藥的開發平台、市場概要 NASH Drug Pipeline and Market Overview
出版日期: 2020年01月06日內容資訊: 英文 18 Pages
簡介

非酒精性脂肪性肝炎(NASH),是非酒精性脂肪肝病(NAFLD)之一。 NASH,特徵是肝臟發炎及肝細胞的損傷,可能引起肝臟的疤痕化(肝硬化)。 NASH專用的醫藥品未獲批准,不過,有許多開發中的產品。

本報告提供非酒精性脂肪性肝炎 (NASH) 治療藥市場相關調查,開發企業,藥物的種類,從階段研究,及市場進入的觀點,約80個藥物候補相關分析。

第1章 摘要整理

  • 簡介
  • 市場摘要
  • 競爭摘要

第2章 非酒精性脂肪性肝炎 (NASH)

  • 概要

第3章 開發中的產品

  • 簡介
  • 開發中的產品

第4章 市場機會

  • 概要
  • 市場預測指標
    • NASH疾病的發生率和盛行率
    • NAFLD的發生率和盛行率
    • 危險因素評估<
    • 價格趨勢<
    • 肝臟移植的統計與趨勢
    • 市場滲透率的預測
    • 全球治療選擇與新的治療方法<
  • 競爭概要
    • Intercept
    • Genfit
    • Allergan
    • Madrigal
    • Immuron
    • Galectin
    • Gilead
目錄
Product Code: 20-053

Non-alcoholic steatohepatitis (NASH) is a type of non-alcoholic fatty liver disease (NAFLD). NASH is characterized by inflammation in the liver and liver cell damage, which can lead to scarring of the liver (cirrhosis). No medications have been approved specifically for NASH but there are numerous products in development. ‘NASH Drug Pipeline and Market Overview’ looks at the almost 80 drug candidates for the treatment of this disease in terms of developer, type of drug, phase study, and market entrance estimate. In addition, the report provides the following data:

  • Estimated Treatment Cost for NASH Therapies, Low-, Mid-, High-Range, 30-day Supply
  • NASH Market Estimates by Global Region, 2025 Forecast (United States & Canada, EMEA, Latin America, Asia Pacific)

In creating its market forecast, Kalorama discusses the indicators that needed to be evaluated to create this estimate, commenting on:

  • NASH Disease Incidence and Prevalence
  • NAFLD Incidence and Prevalence
  • Risk Factor Evaluation
  • Pricing Trends
  • Liver Transplant Statistics and Trends
  • Expected Market Penetration
  • Global Treatment Options and Emerging Therapies

‘NASH Drug Pipeline and Market Overview’ also covers the competitive outlook in the NASH treatment market, noting the activities of the current major players, which include:

  • Intercept
  • Genfit
  • Allergan
  • Madrigal
  • Immuron
  • Galectin
  • Gilead

TABLE OF CONTENTS

CHAPTER 1: EXECUTIVE SUMMARY

  • INTRODUCTION
  • MARKET SUMMARY
  • COMPETITIVE SUMMARY

CHAPTER 2: NASH

  • OVERVIEW

CHAPTER 3: PRODUCTS IN DEVELOPMENT

  • INTRODUCTION
  • PRODUCTS IN DEVELOPMENT
    • Table 3-1: Products in Development for the Treatment of NASH 2019

CHAPTER 4: MARKET OPPORTUNITY

  • OVERVIEW
    • Figure 4-1: NASH Market Estimates by Global Region, 2025 Forecast (United States & Canada, EMEA, Latin America, Asia Pacific)
  • MARKET FORECAST INDICATORS
    • NASH Disease Incidence and Prevalence
    • NAFLD Incidence and Prevalence
    • Risk Factor Evaluation
      • Figure 4-2: Obesity and Diabetes Prevalence Rates (% of Population), 2016
    • Pricing Trends
      • Table 4-1: Estimated Treatment Cost for NASH Therapies, Low-, Mid-, High-Range, 30-day supply
    • Liver Transplant Statistics and Trends
      • Figure 4-3: Liver Transplant Distribution by World Region, 2018 (Europe, Americas, Western Pacific, South-East Asia, Africa, Eastern Mediterranean)
    • Expected Market Penetration
    • Global Treatment Options and Emerging Therapies
  • COMPETITIVE OVERVIEW
    • Intercept
    • Genfit
    • Allergan
    • Madrigal
    • Immuron
    • Galectin
    • Gilead